Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0026986 (myelodysplastic syndrome)
 14,926 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A 46-year-old man with Werner's syndrome was admitted with epigastralgia and body weight loss. The peripheral blood findings showed anemia, thrombocytosis and eosinophilia. Bone marrow aspiration and biopsy revealed increases in eosinophils and megakaryocytes, myelodysplastic change with 6.6% myeloblast, and myelofibrosis. Chromosomal analysis revealed 46, XY, +der(1;7), -7, del(20). He was diagnosed as having myelodysplastic syndrome with myelofibrosis or essential thrombocythemia. Three months later, pancytopenia appeared with a relative increase of blasts positive for CD41 and negative for myeloperoxidase. He died of respiratory failure due to pneumonia. An autopsy revealed severe myelofibrosis with proliferation of megakaryocytes and blasts. A final diagnosis of acute megakaryoblastic leukemia was made. Werner's syndrome is rare, and it is even more unusual to have the complication of acute leukemia with der (1;7) seen in this case.
 ...
PMID:[Werner's syndrome developing acute megakaryoblastic leukemia with der(1;7)]. 902 58

We examined the efficacy of bendamustine in 15 pretreated patients (12 men, 3 women, median age 69 years) with acute myeloid leukaemia (AML) or myelodysplastic syndromes (MDS) 3 AML, 5 sAML, 5 CMML II, 1 RAEB II. Patients belonged to the following cytogenetic groups: 3 complex abnormal karyotypes, 7 normal karyotypes, 1 case with 20q- as sole anomaly and 4 single aberrations. The patients received in median two cycles of bendamustine (range 1-5) with a dose of 100 mg/m(2) at Day 1 + 2 (repeated after 28 days). Nine of 15 patients had no side effects of the treatment, six patients suffered from vomiting and epigastric pain as adverse effects of bendamustine. According to the IWG criteria, no complete remission or reduction of transfusions frequency have been observed. Three patients showed no response, one patient with AML died due to progressive disease. In 11 of 12 patients with initial leukocytosis (median 68,975 microl(-1), range 24,000-149,000 microl(-1)), a significant reduction of leukocytosis was achieved with bendamustine with a median duration of 4 weeks. In summary, treatment with bendamustine in patients with high-risk MDS or sAML with leukocytosis can result in a significant reduction of leukocytes, but fails to achieve hematological responses or improvement of transfusions dependency.
 ...
PMID:A pilot study of bendamustine in elderly patients with high-risk MDS and AML. 1757 66

Acute adrenal failure due to bilateral adrenal haemorrhage is rare and may initially present with non-specific symptoms. It can rapidly progress into a life-threatening condition if not diagnosed promptly. Both traumatic and non-traumatic conditions have been implicated in the aetiology, with the latter been even rarer. We describe the case of a 57-year-old woman presenting with vomiting and epigastric pain and later developing fever and diarrhoea. The patient then deteriorated into shock and primary adrenal insufficiency was identified. A computed tomography scan noted bilateral adrenal haemorrhage. Further investigations showed a sigmoid colon adenocarcinoma and a myelodysplastic syndrome, with monosomy seven. Bilateral non-traumatic adrenal haemorrhage is an infrequent finding and investigating its aetiology can be challenging. In our patient, two simultaneous underlying diseases were identified. To the best of our knowledge, the combination of these two non-traumatic conditions as a cause of acute bilateral adrenal haemorrhage has not been previously reported.
...
PMID:Acute adrenal insufficiency as a first presentation of myelodysplastic syndrome and sigmoid colon adenocarcinoma: a case report. 2598 40